Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HY209 in Healthy Volunteers
NCT06533878Phase 1Enrolling by invitation
- Sponsor
- Kukjeon Co
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NuCerin in Dementia (10 arms), sponsored by Kukjeon Co. Primary endpoints: Maximum Tolerable Dose, Adverse events and 6 more. Started Sep 2023; status: enrolling by invitation.
02
Drugs
NuCerin
03
Conditions
Dementia
Beyond the preview
Go deeper on NCT06533878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533878.